Recent Updates
Recently added Catalysts

Omega DUROS device

Phase 1

Chronic Hepatitis C | Small molecule | Infectious Disease |cbdMD, Inc.|Last Updated: Jun 8, 2011

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLEDBiomarker
Total Trials1
Total Enrollment60

FDA Designations

No designations recorded

Clinical trial landscape

Omega DUROS device · 1 trial · 1 indication

Phase 1 1
NCT00519792Phase 1b Study of Omega DUROS® in Patients With Chronic Hepatitis C Who Relapsed After Prior TreatmentChronic Hepatitis C
COMPLETED60 Analytics
PHASE1COMPLETED
Phase 1b Study of Omega DUROS® in Patients With Chronic Hepatitis C Who Relapsed After Prior Treatment
Chronic Hepatitis CUnlock trial analytics

Study Endpoints

Primary Endpoints

Safety
Week 52
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
1EXPERIMENTALOmega DUROS: Dose 25
2EXPERIMENTALOmega DUROS: Dose 50

Interventions

NameTypeDescription
Omega DUROS deviceDRUGOmega DUROS device 25mcg inserted SC for 48 weeks Omega DUROS device 50mcg inserted SC for 48 weeks
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersNo
Study Sites8

Inclusion Criteria: * Chronic Hepatitis C with HCV genotype 1 infection * Relapse following an end of treatment response after treatment with a pegylated interferon and ribavirin. Exclusion Criteria: * Presence or history of non-HCV chronic liver disease * Treatment with any interferon subsequent...

Countries:United StatesPuerto Rico
Unlock Eligibility Criteria

Frequently asked questions about Omega DUROS device

What is Omega DUROS device used for?

Omega DUROS device is an investigational small molecule being developed for the treatment of chronic Hepatitis C. It is designed for patients who have relapsed after prior treatment. The device is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.

Who makes Omega DUROS device?

Omega DUROS device is being developed by cbdMD, Inc., a company traded on the stock exchange under the ticker symbol YCBD. The company is conducting clinical research to evaluate the safety and efficacy of this investigational therapy for chronic Hepatitis C.

What phase is Omega DUROS device in?

Omega DUROS device is in Phase 1 clinical development. A Phase 1b study has been completed, which involved 60 participants with chronic Hepatitis C who had relapsed after prior treatment. The drug remains investigational and has not received FDA approval.

What clinical trials is Omega DUROS device in?

Omega DUROS device has one completed clinical trial registered as NCT00519792. This was a Phase 1b study conducted in the United States and Puerto Rico, enrolling 60 adults with chronic Hepatitis C who had relapsed after prior treatment. The trial was controlled and randomized.

Is Omega DUROS device the same as Omega DUROS?

Yes, Omega DUROS device is the same as Omega DUROS. The clinical trial NCT00519792 refers to the study as 'Phase 1b Study of Omega DUROS® in Patients With Chronic Hepatitis C Who Relapsed After Prior Treatment.' Both names refer to the same investigational product.